Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al v. Biogen Inc.
Case Number:
1:12-cv-10601
Court:
Nature of Suit:
Other Statutes: False Claims Act
Judge:
Firms
- Baron & Budd
- Bradley Arant
- Conn Kavanaugh
- Cravath Swaine
- DLA Piper
- Greene LLP
- Hogan Lovells
- Miner Siddall
- Partridge Snow
- Pollock Cohen
- Ropes & Gray
- Skadden Arps
- Whistleblower Law Collaborative
- Williams Barber
Companies
- Alexion Pharmaceuticals Inc.
- Biogen Inc.
- Elan Corporation, plc
- Genzyme Corp.
- Huron Consulting Group Inc.
- Jazz Pharmaceuticals Inc.
Government Agencies
Sectors & Industries:
-
October 04, 2022
Inside A Boutique's $900M FCA Deal, Its Latest Milestone Case
A $900 million settlement of doctor-bribing allegations against Biogen shattered False Claims Act records and gave a boutique Boston firm its second history-making lawsuit under the FCA. The lead counsel for whistleblowers in each case spoke with Law360 about how the resolution could change the pharmaceutical industry's kickback culture, how his earlier suit improved drugmaker conduct, and how he built two of the FCA's seminal cases.
-
September 27, 2022
Biogen Whistleblower's $250M Award 'Extraordinary' For FCA
A former pharmaceutical manager's $250 million cut of Biogen's $900 million payments-for-prescriptions settlement is among the largest whistleblower awards in U.S. history, delivering a shot of adrenaline to other False Claims Act cases not backed by the U.S. Department of Justice's muscle, attorneys said Tuesday.
-
September 26, 2022
Biogen Finalizes $900M Deal To End Feds' Kickback Claims
A Massachusetts federal judge gave the final green light Monday to a deal that will see Biogen Inc. pay $900 million to settle decade-old claims with the federal government, as well as several states, that the company paid illegal kickbacks to doctors and other health care professionals.
-
July 20, 2022
Biogen To Pay $900M To Settle Kickback Claims On Trial's Eve
Biogen Inc. has agreed to pay $900 million to settle claims that the company paid illegal kickbacks to doctors and other health care professionals just days before the decade-old case was about to go to trial.